Our mission is to develop and translate novel therapies and predictive biomarkers into clinical research and practice to optimize efficiency, effectiveness, and success in bringing the right therapy to the right patient at the right time.
Geoffrey S. Ginsburg, M.D., Ph.D. is the Director of Genomic Medicine in the Duke Institute for Genome Sciences & Policy. He is also Professor of Medicine and of Pathology at Duke University Medical Center.
Dr. Ginsburg received his M.D. and Ph.D. in biophysics from Boston University. He completed an internal medicine residency at Beth Israel Hospital in Boston. Subsequently, he pursued postdoctoral training in clinical cardiovascular medicine at Beth Israel Hospital and in molecular biology at Children's Hospital as a Bugher Foundation Fellow of the American Heart Association. In 1990 he joined the faculty of Harvard Medical School where he was Director of Preventive Cardiology and led a laboratory in applied genetics of cardiovascular disease. In 1997 he joined Millennium Pharmaceuticals, Inc., as Senior Program Director for Cardiovascular Diseases. In 2000, he was appointed Vice President of Molecular and Personalized Medicine at Millennium, where he was responsible for developing pharmacogenomic strategies for therapeutics, as well as biomarkers for disease and their implementation in the drug development process. He assumed his current position in the Duke Institute for Genome Sciences & Policy in September 2004, and, in 2006, he was also appointed as Co-Director, Duke Translational Medicine Institute.
Dr. Ginsburg has received a number of awards for his research accomplishments, including the Innovator in Medicine Award from Millennium in 2004 and the Basic Research Achievement Award in Cardiovascular Medicine from Duke in 2005. He is a founding member of the Personalized Medicine Coalition, an Associate Editor for The Journal of the American College of Cardiology, and an Associate Editor for Genomic Medicine. He has been an international expert panel member for Genome Canada and is currently a member of: the Board of External Experts for the NHLBI, the Secretary of Veterans Affairs Advisory Council on Genomic Medicine, the Institute of Medicine's Roundtable on Genome Based Research to Human Health. Recently, he was appointed to the Food and Drug Administration's Clinical Pharmacology Advisory Council.
His research interests are in the development of novel paradigms for developing and translating genomic information into medical practice and the integration of personalized medicine into health care.
Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM, J Clin Oncol. 2012 Feb 20;30(6):678. Abstract
Voora D, Ortel TL, Lucas JE, Chi JT, Becker RC, Ginsburg GS, J Thromb Thrombolysis. 2012 Feb 1;. Abstract
Cho AH, Killeya-Jones LA, O'Daniel JM, Kawamoto K, Gallagher P, Haga S, Lucas JE, Trujillo GM, Joy SV, Ginsburg GS, BMC Health Serv Res. 2012;12:16. Abstract
Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, Denny TN, Chen X, Munshaw S, Marshall DJ, Whitesides JF, Drinker MS, Amos JD, Gurley TC, Eudailey JA, Foulger A, DeRosa KR, Parks R, Meyerhoff RR, Yu JS, Kozink DM, Barefoot BE, Ramsburg EA, Khurana S, Golding H, Vandergrift NA, Alam SM, Tomaras GD, Kepler TB, Kelsoe G, Liao HX, Haynes BF, PLoS One. 2011;6(10):e25797. Abstract
Orlando LA, Hauser ER, Christianson C, Powell KP, Buchanan AH, Chesnut B, Agbaje AB, Henrich VC, Ginsburg G, BMC Health Serv Res. 2011;11:264. Abstract
© 2004-2012, Duke Institute for Genome Sciences & Policy. Duke University | Duke Medicine | Interdisciplinary Studies at Duke